Compare Dolby Laboratories, Inc. (DLB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Summit Therapeutics Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.88 (market cap $5.75B), while Summit Therapeutics Inc trades at $15.24 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 2.1× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DLB | SMMT | |
|---|---|---|
Market Cap | $5.75B | $12.06B |
Sector | Industrials | Health |
52-Week High | $75.62 | $26.98 |
52-Week Low | $48.51 | $12.55 |
Enterprise Value | $5.12B | $11.39B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $60.74, down 2.19% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with an 87.61% gross margin and has beaten EPS estimates for four consecutive quarters. Recent news highlights innovation in automotive and broadcast licensing, though revenue growth remains choppy.
The stock presents a compelling opportunity with a consensus price target of $87.50, implying significant upside, but faces near-term execution risks and licensing volatility. Long-term growth drivers in premium audio/visual formats are balanced by macroeconomic sensitivity and competitive pressures.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
